Recombinant 2019-nCoV Papain-Like Protease

货号: RB91EPT114

gui_ge

50ug

biao_da_su_zhu

E.coli

biao_qian

NA

fen_zi_liang

35.8 KDa

biao_guan_fen_zi_liang

34 KDa, reducing conditions

xing_tai

Supplied as a 0.2 μm filtered solution of 20mM Tris-HCl, 10 mM 2-Mercaptoethanol, 20% Glycerol, pH 7.5.

chun_du

Greater than 95% as determined by reducing SDS-PAGE.

huo_xing

Measured by its ability to convert the fluorogenic peptide substrate, Arg-Leu-Arg-Gly-Gly-AMC (RLRGGAMC) to RLRGG and 7-amino-4-methylcoumarin (AMC). The Specific Activity is 241.7 pmol/min/μg.

chu_cun_fang_fa

Store at ≤-70° C, stable for 6 months after receipt.
Store at ≤-70° C, stable for 3 months under sterile conditions after opening.
Please minimize freeze-thaw cycles.

yun_shu_tiao_jian

The product is shipped on dry ice/polar packs.
Upon receipt, store it immediately at the temperature listed below.

bei_jing_shuo_ming

Replication of severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV) requires proteolytic processing of the replicase polyprotein by two viral cysteine proteases, a chymotrypsin-like protease (3CLpro) and a papain-like protease (PLpro). These proteases are important targets for development of antiviral drugs that would inhibit viral replication and reduce mortality associated with outbreaks of SARS-CoV. PLpro is a cysteine protease located within the non-structural protein 3 (NS3) section of the viral polypeptide. PLPro activity is required to process the viral polyprotein into functional, mature subunits; specifically, PLPro cleaves a site at the amino-terminus of the viral replicase region. In addition to its role in viral protein maturation, PLPro possesses a deubiquitinating and deISGylating activity. In vivo, this protease antagonizes innate immunity by inhibiting IRF3-induced production of type I interferons.

本产品仅供科研使用，不用于临床诊断。